NCT05947097招募中1 期
An Open-label, Single-dose Study to Assess the Pharmacokinetics of HSK21542 Injection in Subjects With Varying Degrees of Renal Impairment Compared to the Control Subjects With Normal Renal Function
Haisco Pharmaceutical Group Co., Ltd.1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2023年4月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of HSK21542 in subjects with mild, moderate and severe renal impairment compared to the matched control subjects with normal renal function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects with renal impairment(RI):
- •Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
- •18 years to 79 years (inclusive), male and female;
- •Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m^2));
- •Subjects with medically stable RI until study completion corresponding to the classifications of Renal Function based on GFR: mild RI: 60≤GFR<90 mL/min; moderate RI: 30≤GFR<60 mL/min, severe RI:15≤GFR<30 mL/min;
- •Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests results were deemed appropriate by the investigator;
- •Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities (last more than four weeks in good compliance);
- •Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration.
- •Subjects with normal renal function :
- •Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
- •18 years to 79 years (inclusive), male and female, age and sex must be matched with subjects with RI;
- •Male subjects weight ≥50 kg and female subjects weight ≥45 kg, weight must be matched with subjects with RI. Body mass index (BMI) : 18-30 kg/m^2 (inclusive) (BMI= weight (kg)/height2 (m^2));
- •90≤GFR<130 mL/min;
- •Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests results were deemed appropriate by the investigator;
- •Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for comorbidities (last more than four weeks in good compliance);
- •Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration.
排除标准
- •Subjects who have a allergic to any component of HSK21542 injection or allergic history to opiates, such as urticaria (opiate-related adverse reactions such as constipation and nausea are not included as exclusion criteria in this study);
- •Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening;
- •Have conditions that may affect drug absorption, distribution, metabolism, or excretion (e.g., disease, drugs or surgery);
- •Acute renal failure;
- •Smoking more than 5 cigarettes per day within 3 months prior to screening or smoking during the study;
- •Average alcohol intake is more than 14 unit per week (1unit=17.7 mL alcohol , 1 unit=357mL 5% alcohol beer, or 43mL 40% alcohol spirit, or 147mL 12% alcohol wine) within the 3 months prior to screening, or taking any alcohol during study or a positive ethanol breath test at screening;
- •Drug abuse history within 5 years prior to screening, or positive urine drug screen at screening;
- •History of high consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) ,consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration;
- •Participation in another clinical trial within 3 months before screening;
- •Blood donation (or blood loss) ≥400 mL, or receiving blood products to improve anemia within 3 months prior to the screening;
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2 × upper limit of normal, or bilirubin > 1.5 × upper limit of normal;
- •Have a positive result for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or anti-treponema pallidum specific antibody;
- •A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial;
- •Not suitable for this study as judged by the investigator.
研究组 & 干预措施
Mild Renal Impairment
Experimental
干预措施: HSK21542 Injection (Drug)
Moderate Renal Impairment
Experimental
干预措施: HSK21542 Injection (Drug)
Severe Renal Impairment
Experimental
干预措施: HSK21542 Injection (Drug)
Normal Renal function
Experimental
干预措施: HSK21542 Injection (Drug)
结局指标
主要结局
Cmax
时间窗: From the start to 240 hours after bolus
The maximun plasma concentration of HSK21542
AUC0-t
时间窗: From the start to 240 hours after bolus
Area under the concentration-time curve from time zero to time of last quantifiable concentration
AUC0-inf
时间窗: From the start to 240 hours after bolus
Area under the concentration-time curve from time zero extrapolated to infinite time
次要结局
- Tmax(From the start to 240 hours after bolus)
- t1/2(From the start to 240 hours after bolus)
- CL(From the start to 240 hours after bolus)
- Vz(From the start to 240 hours after bolus)
- Ae(Predose and 72 hours after dosing)
- Fe(Predose and 72 hours after dosing)
- CLr(Predose and 72 hours after dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of GSK3511294 in Healthy Chinese ParticipantsAsthmaNCT05140200GlaxoSmithKline20
已完成
1 期
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)Human Immunodeficiency Virus (HIV) InfectionNCT04515641Merck Sharp & Dohme LLC12
已完成
1 期
A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal ImpairmentRenal ImpairmentNCT05916573Haisco Pharmaceutical Group Co., Ltd.32
已完成
2 期
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4Chronic Kidney DiseaseNCT04707573Akebia Therapeutics22
已完成
2 期
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised ChildrenRSV InfectionNCT04484935AstraZeneca100